RAPS In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA's James Dillard: Deputy Director Bram Zuckerman will become acting director of FDA's Division of Cardiovascular and Respiratory Devices Dec. 3. Current DCRD Director James Dillard departs Nov. 30 for the private sector, where he has accepted the position of VP-science and technology at U.S. Tobacco. Dillard, a fourteen-year FDA veteran, has held the DCRD position for the last 18 months and overseen the reorganization of the division (1"The Gray Sheet" July 24, 2000, p. 10)...
You may also be interested in...
Former FDA cardiology chief Dillard
Jim Dillard is elected to M Squared Associates board of directors. Dillard, VP-science & technology at US Smokeless Tobacco, left CDRH in November 2001 (1"The Gray Sheet" Nov. 12, 2001, p. 7)...
Former FDA cardiology chief Dillard
Jim Dillard is elected to M Squared Associates board of directors. Dillard, VP-science & technology at US Smokeless Tobacco, left CDRH in November 2001 (1"The Gray Sheet" Nov. 12, 2001, p. 7)...
AdvaMed Device Submissions Workshop In Brief
New 510(k) paradigm: Level 2 guidance document on 510(k)s is expected to be released by the end of the summer, Office of Device Evaluation Premarket Notification Staff Director Heather Rosecrans tells attendees at AdvaMed's device submissions workshop held June 6-7 in Rockville, Maryland. "We're right at the process of updating the new paradigm, and that's going to go through the GGP [good guidance practices] process. We're going to consider the truthful and accurate...statement in place of the declaration of conformity...with design controls, because there's no end and no beginning and there has been some confusion." Rosecrans highlighted one change for manufacturers submitting 510(k)s: "validation will have to be completed prior to going to market with your device"...